BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 23490385)

  • 21. [Durability of HBeAg seroconversion in lamivudine treatment of chronic hepatitis B patients].
    Zhu M; Xu B; Yao GB
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):534-6. PubMed ID: 16042894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of long-term lamivudine in chronic hepatitis B virus-infected children.
    Ozgenç F; Arikan C; Sertoz RY; Nart D; Aydogdu S; Yagci RV
    Antivir Ther; 2004 Oct; 9(5):729-32. PubMed ID: 15535410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B.
    Kim HS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    Gastroenterology; 2009 Feb; 136(2):505-12. PubMed ID: 19101558
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of hepatitis B surface antigen (HBsAg) in identifying true inactive HBsAg carriers infected with genotype C hepatitis B virus.
    Yim SY; Um SH; Jung JY; Seo YS; Yim HJ; Ryu HS; Chun HJ; Jeen YT; Kim CD; Keum B; Lee HS
    J Clin Gastroenterol; 2014 Feb; 48(2):166-71. PubMed ID: 24045280
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.
    Moucari R; Korevaar A; Lada O; Martinot-Peignoux M; Boyer N; Mackiewicz V; Dauvergne A; Cardoso AC; Asselah T; Nicolas-Chanoine MH; Vidaud M; Valla D; Bedossa P; Marcellin P
    J Hepatol; 2009 Jun; 50(6):1084-92. PubMed ID: 19376603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term follow-up of chronic hepatitis B virus infection in children of different ethnic origins.
    Marx G; Martin SR; Chicoine JF; Alvarez F
    J Infect Dis; 2002 Aug; 186(3):295-301. PubMed ID: 12134225
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Effect of interferon-alpha treatment in children with hepatitis B e antigen-positive chronic hepatitis B virus infection: a meta-analysis of follow-up for six months to two years].
    Lin ZQ; Fang F; Guo ZF; Chen Q
    Zhonghua Er Ke Za Zhi; 2007 Aug; 45(8):592-8. PubMed ID: 18021533
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion.
    Chen YC; Huang SF; Chu CM; Liaw YF
    J Viral Hepat; 2012 Feb; 19(2):138-46. PubMed ID: 22239503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Entecavir treatment of children 2-16 years of age with chronic hepatitis B infection.
    Saadah OI; Sindi HH; Bin-Talib Y; Al-Harthi S; Al-Mughales J
    Arab J Gastroenterol; 2012 Jun; 13(2):41-4. PubMed ID: 22980589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir.
    Reijnders JG; Rijckborst V; Sonneveld MJ; Scherbeijn SM; Boucher CA; Hansen BE; Janssen HL
    J Hepatol; 2011 Mar; 54(3):449-54. PubMed ID: 21112655
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters.
    Tseng TC; Liu CJ; Su TH; Wang CC; Chen CL; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2011 Aug; 141(2):517-25, 525.e1-2. PubMed ID: 21672542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Different models of HBeAg seroconversion predicated by on-treatment ALT and HBV DNA profiles.
    You H; Ma H; Liu T; Cong M; Wang P; Ou X; Wang X; Ren J; Li H; Wang B; Jia J
    J Viral Hepat; 2009 Dec; 16(12):876-82. PubMed ID: 19635048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM; Barbaro G; Francavilla R; Romano M; Barbarini G; Mazzoni E; Mecenate F; Paffetti A; Barlattani A; Struglia C; Villani R; Nauri L; Nosotti L; Armignacco O; Ferri F; Camporiondo MP; Soccorsi F;
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatitis B surface antigen loss and sustained viral suppression in Asian chronic hepatitis B patients: A community-based real-world study.
    Wong RJ; Nguyen MT; Trinh HN; Chan C; Huynh A; Ly MT; Nguyen HA; Nguyen KK; Torres S; Yang J; Liu B; Garcia RT; Bhuket T; Baden R; Levitt B; da Silveira E; Gish RG
    J Viral Hepat; 2017 Dec; 24(12):1089-1097. PubMed ID: 28581644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients.
    Kwak MS; Cho EJ; Jang ES; Lee JH; Yu SJ; Kim YJ; Yoon JH; Lee HS
    Digestion; 2011; 84 Suppl 1():23-8. PubMed ID: 22156482
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.
    Wang CC; Tseng KC; Peng CY; Hsieh TY; Lin CL; Su TH; Tseng TC; Hsu CS; Lin HH; Kao JH
    J Gastroenterol Hepatol; 2013 Jan; 28(1):46-50. PubMed ID: 22989322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients.
    Cai W; Xie Q; An B; Wang H; Zhou X; Zhao G; Guo Q; Gu R; Bao S
    J Clin Virol; 2010 May; 48(1):22-6. PubMed ID: 20233672
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of puberty onset on spontaneous hepatitis B virus e antigen seroconversion in men.
    Wu JF; Tsai WY; Hsu HY; Ni YH; Chen HL; Tsuei DJ; Chang MH
    Gastroenterology; 2010 Mar; 138(3):942-8.e1. PubMed ID: 19962986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatitis B surface antigen seroconversion is associated with favourable long-term clinical outcomes during lamivudine treatment in HBeAg-negative chronic hepatitis B patients.
    Idilman R; Cinar K; Seven G; Bozkus Y; Elhan A; Bozdayi M; Yurdaydin C; Bahar K
    J Viral Hepat; 2012 Mar; 19(3):220-6. PubMed ID: 22329377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B.
    Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R
    J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.